{"entity":{"id":"flt3i-plus-7-3","kind":"pairing","name":"FLT3 inhibitor + intensive chemotherapy","aka":[],"tldr":"Adding a FLT3 blocker to standard chemotherapy is the proven way to improve survival in FLT3-mutated AML.","summary":"This combination adds a FLT3 inhibitor, quizartinib or midostaurin, to intensive cytarabine and anthracycline induction chemotherapy, the 7+3 regimen, in FLT3-mutated acute myeloid leukaemia. Chemotherapy debulks the leukaemia while FLT3 inhibition removes the proliferative driver and suppresses the resistant subclone that would otherwise cause relapse. Two positive phase 3 trials with different molecules, RATIFY with midostaurin and QuANTUM-First with quizartinib, both improved overall survival, and quizartinib is continued as maintenance after induction. Maintenance with gilteritinib after transplant, tested in MORPHO, adds further protection in patients who are MRD-positive.","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT00651261: RATIFY (CALGB 10603)","url":"https://clinicaltrials.gov/study/NCT00651261"},{"label":"ClinicalTrials.gov NCT02668653: QuANTUM-First","url":"https://clinicaltrials.gov/study/NCT02668653"}],"tags":[],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":["flt3"],"drugs":["midostaurin","quizartinib","gilteritinib","cytarabine-7-3"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["ratify","quantum-first"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"a":"quizartinib","b":"cytarabine-7-3","rationale":"Chemotherapy debulks; FLT3 inhibition removes the proliferative driver and suppresses the resistant subclone that would otherwise relapse.","evidence":"Two positive phase 3 trials with different molecules.","pairingType":"combination"},"route":"/pairings/flt3i-plus-7-3/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"aml-flt3","kind":"cancer","name":"FLT3-mutated acute myeloid leukaemia","route":"/cancers/aml-flt3/"}],"target":[{"id":"flt3","kind":"target","name":"FLT3","route":"/targets/flt3/"}],"drug":[{"id":"cytarabine-7-3","kind":"drug","name":"Cytarabine + anthracycline ('7+3')","route":"/drugs/cytarabine-7-3/"},{"id":"gilteritinib","kind":"drug","name":"Gilteritinib","route":"/drugs/gilteritinib/"},{"id":"midostaurin","kind":"drug","name":"Midostaurin","route":"/drugs/midostaurin/"},{"id":"quizartinib","kind":"drug","name":"Quizartinib","route":"/drugs/quizartinib/"}],"trial":[{"id":"quantum-first","kind":"trial","name":"QuANTUM-First","route":"/trials/quantum-first/"},{"id":"ratify","kind":"trial","name":"RATIFY (CALGB 10603)","route":"/trials/ratify/"}],"paper":[{"id":"paper-quantum-first-quizartinib-lancet-2023","kind":"paper","name":"QuANTUM-First: quizartinib added to intensive chemotherapy and continued as maintenance in newly diagnosed FLT3-ITD AML","route":"/key-papers/paper-quantum-first-quizartinib-lancet-2023/"}]}}